| Literature DB >> 35291978 |
Chloe A Teasdale1,2,3, Judith Odondi4, Catherine Kidiga4, Michelle Choy4, Ruby Fayorsey4, Bernadette Ngeno5, Boniface Ochanda6, Agnes Langat6, Catherine Ngugi7, Tegan Callahan5, Surbhi Modi5, Mark Hawken4, Doris Odera4, Elaine J Abrams4,8,9.
Abstract
BACKGROUND: Pregnant and breastfeeding adolescents and young women living with HIV (AYWLH) have lower retention in prevention of mother-to-child transmission (PMTCT) services compared to older women.Entities:
Keywords: Adolescent pregnancy; Antiretroviral therapy; Group antenatal care; Prevention of mother-to-child transmission of HIV; Retention
Mesh:
Year: 2022 PMID: 35291978 PMCID: PMC8925235 DOI: 10.1186/s12884-022-04527-z
Source DB: PubMed Journal: BMC Pregnancy Childbirth ISSN: 1471-2393 Impact factor: 3.007
Fig. 1Project HOPE group care model for adolescent and young pregnant women living with HIV developed by ICAP at Columbia University
Fig. 2Antiretroviral treatment (ART) status information in antenatal care (ANC) among newly enrolled pregnant adolescent and young women living with HIV (AYWLH) < 25 years of age in the pre- and post-periods. ANC: antenatal care; ART: antiretroviral therapy; LTFU: loss to follow-up
Characteristics of pregnant adolescent and young women living with HIV (AYWLH) < 25 years of age newly enrolled in antenatal (ANC) services with antiretroviral therapy (ART) start date at seven HOPE project facilities in Kenya in the pre- and post-periods (N = 543)
| N | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47 | 21.1 | 176 | 78.9 | 223 | 100.0 | 53 | 16.6 | 267 | 83.4 | 320 | 100.0 | 46 | 18.0 | 209 | 82.0 | 255 | 100.0 | |||
22 (16–29) | 22 (16–26) | 22 (16–26) | 22 (14–28) | 20 (14–26) | 20 (14–26) | 0.11 | 24 (14–28) | 20 (13–26) | 20 (13–26) | 0.16 | ||||||||||
| 12 | 26.1 | 57 | 27.3 | 69 | 27.1 | |||||||||||||||
| 1st | 9 | 19.2 | 31 | 17.7 | 40 | 18.0 | 15 | 28.3 | 69 | 25.8 | 84 | 26.3 | 0.06 | 20 | 43.5 | 108 | 51.7 | 128 | 50.2 | 0.05 |
| 2nd | 22 | 46.8 | 109 | 62.3 | 131 | 59.0 | 24 | 45.3 | 139 | 52.1 | 163 | 50.9 | 14 | 30.4 | 44 | 21.1 | 58 | 22.8 | ||
| 3rd | 16 | 34.0 | 35 | 20.0 | 51 | 23.0 | 14 | 26.4 | 59 | 22.1 | 73 | 22.8 | ||||||||
| 0 | 30 | 63.8 | 34 | 19.3 | 64 | 28.7 | 41 | 77.4 | 84 | 31.6 | 125 | 39.2 | 0.06 | 35 | 76.1 | 73 | 35.1 | 108 | 42.5 | 0.03 |
| 1–3 | 17 | 36.2 | 137 | 77.8 | 154 | 69.1 | 12 | 22.6 | 180 | 67.7 | 192 | 60.2 | 11 | 23.9 | 133 | 63.9 | 144 | 56.7 | ||
| > 3 | 0 | 0.0 | 5 | 2.8 | 5 | 2.2 | 0 | 0.0 | 2 | 0.8 | 2 | 0.6 | 0 | 0.0 | 2 | 1.0 | 2 | 0.8 | ||
| 30 | 63.8 | 152 | 86.4 | 182 | 81.6 | 32 | 60.4 | 214 | 80.2 | 246 | 76.9 | 0.20 | 28 | 60.9 | 163 | 78.0 | 191 | 74.9 | 0.10 | |
| Newly diagnosed | 32 | 68.1 | 81 | 46.0 | 113 | 50.7 | 26 | 49.1 | 93 | 34.8 | 119 | 37.2 | < 0.001 | 22 | 47.8 | 77 | 36.8 | 99 | 38.8 | < 0.01 |
| Known HIV-positive | 15 | 31.9 | 95 | 54.0 | 110 | 49.3 | 27 | 50.9 | 174 | 65.2 | 201 | 62.8 | 24 | 52.2 | 132 | 63.2 | 156 | 61.2 | ||
| On ART at first ANC | 11 | 23.4 | 57 | 32.4 | 68 | 30.5 | 20 | 37.7 | 142 | 53.2 | 162 | 50.6 | < 0.0001 | 17 | 37.0 | 112 | 53.6 | 129 | 50.6 | < 0.0001 |
| Started ART first ANC (≤ 7 days) | 29 | 61.7 | 90 | 51.1 | 119 | 53.4 | 30 | 56.6 | 102 | 38.2 | 132 | 41.3 | 26 | 56.5 | 81 | 38.8 | 107 | 42.0 | ||
| Started ART > 7 days firs ANC | 7 | 14.9 | 29 | 16.5 | 36 | 16.1 | 3 | 5.7 | 23 | 8.6 | 26 | 8.1 | 3 | 6.5 | 16 | 7.7 | 19 | 7.4 | ||
| TDF + 3TC + EFV | 46 | 97.9 | 150 | 85.2 | 196 | 87.9 | 48 | 90.6 | 247 | 92.5 | 295 | 92.2 | 0.08 | 41 | 89.1 | 191 | 91.4 | 232 | 91.0 | 0.39 |
| Other | 1 | 2.1 | 26 | 14.8 | 27 | 12.1 | 5 | 9.4 | 20 | 7.5 | 25 | 7.8 | 5 | 10.9 | 18 | 8.6 | 23 | 9.0 | ||
| 46 | 86.8 | 209 | 78.3 | 255 | 79.7 | 46 | 100.0 | 209 | 100.0 | 255 | 100.0 | |||||||||
| Median number of visits (IQR) | 5 (4–8) | 7 (5–9) | 7 (5–9) | 5 (4–8) | 7 (5–9) | 7 (5–9) | ||||||||||||||
* Age group differences within period (pre and post) statistically significant p < 0.05
TDF tenofovir, 3TC Lamivudine, EFV Efavirenz
Incidence rates, loss to follow-up among adolescent and young women living with HIV (AYWLH) < 25 years of age newly enrolled in antenatal care (ANC) services with antiretroviral therapy (ART) start date at seven HOPE project facilities in Kenya (N = 543)
| < 20 years | 6 | 255 | 0.0236 | 2.36 | 1.06–5.25 | 14.2 |
| 20–24 years | 15 | 969 | 0.0155 | 1.55 | 0.93–2.57 | 9.3 |
| Total | 21 | 1224 | 0.0172 | 1.72 | 1.12–2.63 | 10.3 |
| < 20 years | 4 | 283 | 0.0141 | 1.41 | 0.53–3.77 | 8.5 |
| 20–24 years | 22 | 1430 | 0.0154 | 1.55 | 1.01–2.34 | 9.3 |
| Total | 26 | 1713 | 0.0152 | 1.52 | 1.03–2.23 | 9.1 |
| < 20 years | 2 | 257 | 0.0078 | 0.78 | 0.19–3.11 | 4.7 |
| 20–24 years | 13 | 1153 | 0.0113 | 1.13 | 0.65–1.94 | 6.8 |
| Total | 15 | 1410 | 0.0106 | 1.06 | 0.64–1.76 | 6.4 |
Incidence rate ratios (IRR) for loss to follow-up in first 6 months after first ANC among adolescent and young women living with HIV (AYWLH) < 25 years among those with antiretroviral therapy (ART) start dates by age group, Kenya (N = 543)
| | ||||||
| Gestational age weeks | 0.96 | 0.88–1.05 | 0.42 | 0.99 | 0.97–1.02 | 0.65 |
| Parity 1 + (ref: 0) | 0.16 | 0.02–1.12 | 0.07 | 1.02 | 0.48–2.16 | 0.96 |
| Known HIV + at first ANC (ref: newly diagnosed) | 0.08 | 0.02–0.37 | < 0.01 | 0.40 | 0.15–1.04 | 0.06 |
| On ART at first ANC (ref: started ART first ANC) | 2.83 | 0.62–12.98 | 0.18 | 0.66 | 0.44–0.98 | 0.04 |
| | ||||||
| Gestational age weeks | 0.98 | 0.90–1.08 | 0.71 | 0.99 | 0.96–1.01 | 0.30 |
| Parity 1 + (ref: 0) | 0.23 | 0.02–2.09 | 0.18 | 0.98 | 0.41–2.35 | 0.97 |
| Known HIV + at first ANC (ref: newly diagnosed) | – | – | – | 0.52 | 0.16–1.71 | 0.29 |
| On ART at first ANC (ref: started ART first ANC) | 1.89 | 0.19–18.98 | 0.59 | 0.50 | 0.31–0.80 | < 0.01 |
Adjusted models for women < 20 years did not include a corrected for clustering within facility as sparse did not allow for model convergence; 95%CI: 95% confidence interval (adjusted for all variables included listed and intrasite clustering by facility); – indicates estimates that could not be generated due to sparse data
Adolescent and young women living with HIV (AYWLH) < 25 years of age whose infants received 6–8 week PCR HIV testing and test results in the pre- and post-periods in Kenya (among those eligiblea) (N = 514)
| HIV-exposed infants (HEI) tested 6–8 weeks | ||||||||||||
| Pre-period | Post-period (All) | Adjusted risk ratio | 95% CI | Post-period (HOPE) | Adjusted risk ratio | 95%CI | ||||||
| N | % | N | % | N | % | |||||||
| < 20 years | 47 | 50 | 43 | |||||||||
| Infants tested | 30 | 63.8 | 36 | 72.0 | 1.11 | 0.89–1.39 | 0.35 | 33 | 76.7 | 1.19 | 0.93–1.53 | 0.17 |
| 20–24 years | 176 | 232 | 180 | |||||||||
| Infants tested | 123 | 69.9 | 182 | 78.4 | 1.10 | 1.02–1.19 | 0.01 | 152 | 84.4 | 1.19 | 1.13–1.26 | < 0.0001 |
| All | 223 | 282 | 223 | |||||||||
| Infants tested | 153 | 68.6 | 218 | 77.3 | 1.10 | 1.01–1.21 | 0.04 | 185 | 83.0 | 1.20 | 1.10–1.31 | < 0.0001 |
| HIV-exposed infants (HEI) PCR Test Results | ||||||||||||
| Pre-period | Post-period (All) | Post-period (HOPE) | ||||||||||
| N | % | N | % | N | % | |||||||
| < 20 years | 30 | 36 | 33 | |||||||||
| Positive | 0 | 0.0 | 1 | 2.8 | 1 | 3.0 | ||||||
| Negative | 28 | 93.3 | 34 | 94.4 | 32 | 97.0 | ||||||
| Unknown | 2 | 6.7 | 1 | 2.8 | 0 | 0.0 | ||||||
| 20–24 years | 123 | 182 | 152 | |||||||||
| Positive | 2 | 1.6 | 3 | 1.7 | 3 | 2.0 | ||||||
| Negative | 118 | 95.9 | 174 | 95.6 | 145 | 95.4 | ||||||
| Unknown | 3 | 2.4 | 5 | 2.8 | 4 | 2.6 | ||||||
| All | 153 | 218 | 185 | |||||||||
| Positive | 2 | 1.3 | 4 | 1.8 | 4 | 2.2 | ||||||
| Negative | 146 | 95.4 | 208 | 95.4 | 177 | 95.7 | ||||||
| Unknown | 5 | 3.3 | 6 | 2.8 | 4 | 2.2 | ||||||
aInfants estimated to be at least 6 weeks of age at the time of data collection
**p-values for the comparison of testing of HEI in the pre vs. post period are from modified Poisson (relative risk) regression models adjusted for the following variables measured at the first antenatal care visit: age, gestational age in weeks, parity, known HIV-positive status and on ART